FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2131368811> ?p ?o ?g. }

• W2131368811 endingPage "1183" @default.
• W2131368811 startingPage "1177" @default.
• W2131368811 abstract "In view of recent advances in the development of antifungal agents, this study examined the possible synergy of two new antifungal agents, terbinafine and amorolfine. The study compared two different courses of terbinafine treatment combined with amorolfine 5% solution nail lacquer. Terbinafine was given orally for 6 (AT6 group) or 12 weeks (AT12 group) and amorolfine nail lacquer applied weekly for 15 months. A control group received terbinafine alone for 12 weeks. This was a randomized, prospective, open study of severe dermatophyte toenail onychomycosis with matrix region involvement. Nail samples were taken before the start of the study, at inclusion and at the visits at 6 weeks, 3, 9, 15 and 18 months. To assess the value of such combined therapy we chose an early parameter as the principal outcome variable, which was the result of mycological examination, including direct microscopy and culture, at 3 months (allowing a margin of 15 days). The secondary parameters of success were the mycological results at the later visits, clinical evaluation and a combined mycological-clinical response. Safety and tolerance were also assessed. Adverse events were recorded and liver function tests were performed monthly during the terbinafine treatment. Of the 147 patients included in the trial, 121 attended the 3-month visit, within a time limit of 15 days of 3 months after the beginning of treatment: 40 in the AT6 group, 40 in the AT12 group and 41 in the control group. In all, 32 of 121 patients (26. 4%) had negative mycological results on direct microscopy and culture: 14 of 40 (35.0%) in the AT6 group, 11 of 40 (27.5%) in the AT12 group and seven of 41 (17.1%) in the control group. The cure rate for the global (mycological and clinical cure) response measured at 18 months in 145 patients was 44.0% (22 patients) in the AT6 group, 72.3% (34 patients) in the AT12 group and 37.5% (18 patients) in the terbinafine group. These results suggest that the combination of amorolfine and terbinafine may be of value in the treatment of severe onychomycosis. At the same time a pilot pharmacoeconomic analysis was performed demonstrating a better cost per cure ratio for the patients receiving combination treatment." @default.
• W2131368811 created "2016-06-24" @default.
• W2131368811 creator A5003507854 @default.
• W2131368811 creator A5018376699 @default.
• W2131368811 creator A5036540907 @default.
• W2131368811 creator A5052194989 @default.
• W2131368811 creator A5054657159 @default.
• W2131368811 creator A5056671457 @default.
• W2131368811 creator A5067929287 @default.
• W2131368811 creator A5071766768 @default.
• W2131368811 creator A5080685139 @default.
• W2131368811 date "2000-06-01" @default.
• W2131368811 modified "2023-10-10" @default.
• W2131368811 title "A randomized trial of amorolfine 5% solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycoses affecting the matrix region" @default.
• W2131368811 cites W1503360094 @default.
• W2131368811 cites W1975365379 @default.
• W2131368811 cites W1981034405 @default.
• W2131368811 cites W1984254136 @default.
• W2131368811 cites W1990195226 @default.
• W2131368811 cites W1990620575 @default.
• W2131368811 cites W2003293898 @default.
• W2131368811 cites W2023214486 @default.
• W2131368811 cites W2023767868 @default.
• W2131368811 cites W2025348331 @default.
• W2131368811 cites W2026020458 @default.
• W2131368811 cites W2049731264 @default.
• W2131368811 cites W2050759832 @default.
• W2131368811 cites W2058813334 @default.
• W2131368811 cites W2069193378 @default.
• W2131368811 cites W2069686206 @default.
• W2131368811 cites W2105671058 @default.
• W2131368811 cites W2127255965 @default.
• W2131368811 cites W2150063801 @default.
• W2131368811 cites W2161450783 @default.
• W2131368811 cites W2167842389 @default.
• W2131368811 cites W4251333564 @default.
• W2131368811 cites W4322697976 @default.
• W2131368811 doi "https://doi.org/10.1046/j.1365-2133.2000.03545.x" @default.
• W2131368811 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10848743" @default.
• W2131368811 hasPublicationYear "2000" @default.
• W2131368811 type Work @default.
• W2131368811 sameAs 2131368811 @default.
• W2131368811 citedByCount "125" @default.
• W2131368811 countsByYear W21313688112012 @default.
• W2131368811 countsByYear W21313688112013 @default.
• W2131368811 countsByYear W21313688112014 @default.
• W2131368811 countsByYear W21313688112015 @default.
• W2131368811 countsByYear W21313688112016 @default.
• W2131368811 countsByYear W21313688112017 @default.
• W2131368811 countsByYear W21313688112018 @default.
• W2131368811 countsByYear W21313688112019 @default.
• W2131368811 countsByYear W21313688112020 @default.
• W2131368811 countsByYear W21313688112021 @default.
• W2131368811 countsByYear W21313688112022 @default.
• W2131368811 crossrefType "journal-article" @default.
• W2131368811 hasAuthorship W2131368811A5003507854 @default.
• W2131368811 hasAuthorship W2131368811A5018376699 @default.
• W2131368811 hasAuthorship W2131368811A5036540907 @default.
• W2131368811 hasAuthorship W2131368811A5052194989 @default.
• W2131368811 hasAuthorship W2131368811A5054657159 @default.
• W2131368811 hasAuthorship W2131368811A5056671457 @default.
• W2131368811 hasAuthorship W2131368811A5067929287 @default.
• W2131368811 hasAuthorship W2131368811A5071766768 @default.
• W2131368811 hasAuthorship W2131368811A5080685139 @default.
• W2131368811 hasConcept C126322002 @default.
• W2131368811 hasConcept C141071460 @default.
• W2131368811 hasConcept C16005928 @default.
• W2131368811 hasConcept C168563851 @default.
• W2131368811 hasConcept C191897082 @default.
• W2131368811 hasConcept C192562407 @default.
• W2131368811 hasConcept C197934379 @default.
• W2131368811 hasConcept C2777071850 @default.
• W2131368811 hasConcept C2777220567 @default.
• W2131368811 hasConcept C2777852167 @default.
• W2131368811 hasConcept C2778236110 @default.
• W2131368811 hasConcept C2779548794 @default.
• W2131368811 hasConcept C535046627 @default.
• W2131368811 hasConcept C71924100 @default.
• W2131368811 hasConceptScore W2131368811C126322002 @default.
• W2131368811 hasConceptScore W2131368811C141071460 @default.
• W2131368811 hasConceptScore W2131368811C16005928 @default.
• W2131368811 hasConceptScore W2131368811C168563851 @default.
• W2131368811 hasConceptScore W2131368811C191897082 @default.
• W2131368811 hasConceptScore W2131368811C192562407 @default.
• W2131368811 hasConceptScore W2131368811C197934379 @default.
• W2131368811 hasConceptScore W2131368811C2777071850 @default.
• W2131368811 hasConceptScore W2131368811C2777220567 @default.
• W2131368811 hasConceptScore W2131368811C2777852167 @default.
• W2131368811 hasConceptScore W2131368811C2778236110 @default.
• W2131368811 hasConceptScore W2131368811C2779548794 @default.
• W2131368811 hasConceptScore W2131368811C535046627 @default.
• W2131368811 hasConceptScore W2131368811C71924100 @default.
• W2131368811 hasIssue "6" @default.
• W2131368811 hasLocation W21313688111 @default.
• W2131368811 hasLocation W21313688112 @default.
• W2131368811 hasOpenAccess W2131368811 @default.
• W2131368811 hasPrimaryLocation W21313688111 @default.
• W2131368811 hasRelatedWork W134615286 @default.

• next